OpenLobby.EU
Explore

Koninklijke Philips

Philips

Philips is a health technology company focused on diagnostic imaging, ultrasound, patient monitoring, and personal health solutions.

Lobbying Activity

Meeting with Olivér Várhelyi (Commissioner) and

1 Dec 2025 · Digital and AI as an enabler in healthcare

Meeting with Ingeborg Ter Laak (Member of the European Parliament)

25 Nov 2025 · Medical Device Regulation, AI Act, Digital Omnibus

Meeting with Tomislav Sokol (Member of the European Parliament, Shadow rapporteur) and Novo Nordisk A/S and Haleon

18 Nov 2025 · Health Policy

Philips urges EU to remove barriers for circular healthcare

16 Oct 2025
Topic — The EU is consulting on a new Circular Economy Act for sustainable production.
Message — Philips calls for a legal framework that removes barriers to circularity. Refurbished devices should meet regulations active at their original sale date. Public procurement should include mandatory weighting for sustainability and circular practices.123
Why — These measures would reduce administrative costs and open markets for refurbished medical technologies.45
Impact — Manufacturers of new medical gear may face competition from cheaper refurbished alternatives.6
Read full response

Meeting with Sander Smit (Member of the European Parliament)

15 Oct 2025 · Exchange of views duurzaamheid

Philips urges sectoral approach for AI medical devices in Digital Omnibus

14 Oct 2025
Topic — EU regulatory simplification of digital rules on AI, data and cybersecurity.
Message — Philips requests a sectoral approach for AI-enabled medical devices by including relevant high-risk AI requirements in the Medical Device Regulation rather than the AI Act. They also seek extended application dates and harmonised cybersecurity requirements across NIS2, Cyber Resilience Act and other legislation.123
Why — This would reduce parallel certification processes and avoid working with Notified Bodies lacking medical technology expertise.45
Impact — Patients lose access to innovative AI medical devices that cannot reach the EU market due to bottlenecks.67
Read full response

Meeting with Hanna Anttilainen (Cabinet of Executive Vice-President Stéphane Séjourné)

14 Oct 2025 · Challenges faced by the medical devices industry

Philips Calls for Centralized Governance to Fix EU Medical Device Rules

6 Oct 2025
Topic — Simplifying EU regulations for medical devices to ensure patient safety and competitiveness.
Message — Philips wants a centralized governance structure to harmonize certification procedures across notified bodies, with fixed prices and binding timelines. They seek abolishment of routine recertification and better alignment with international standards like IMDRF and MDSAP.1234
Why — This would reduce certification delays and costs from unpredictable notified body processes.567
Read full response

Philips urges EU to speed device approvals and boost health innovation funding

3 Oct 2025
Topic — EU framework to strengthen Europe's innovation ecosystem and competitiveness for innovative companies.
Message — Philips requests faster medical device approvals, ambitious health innovation funding including public-private partnerships, regulatory sandboxes across EU laws, and modernized procurement rules. They seek close-to-market technology development programs and large-scale deployment funding for hospitals.12345
Why — This would reduce their four-times-longer EU approval times and five-times-higher certification costs versus the US.6
Impact — Smaller competitors without resources to navigate fragmented regulations and lengthy approval processes lose market access.7
Read full response

Meeting with Chiara Galiffa (Cabinet of Commissioner Maroš Šefčovič) and MedTech Europe and

25 Sept 2025 · EU – US relations

Philips urges EU to invest in medical tech to tackle cardiovascular diseases

16 Sept 2025
Topic — Future EU plan addressing prevention, diagnosis and treatment of cardiovascular diseases.
Message — Philips requests dedicated EU funding for cardiovascular health infrastructure, training, and research, with specific targets for reducing premature mortality. They call for Member States to be incentivized to invest in effective technologies and to establish minimum standards for stroke care and cardio-oncology programs across the EU.1234
Why — This would expand the market for their cardiac monitoring, imaging technologies, and AI-enhanced diagnostic solutions.567
Impact — Patients in Member States with slower adoption lose access to life-saving stroke treatments available elsewhere.8910
Read full response

Meeting with Saila Rinne (Head of Unit Communications Networks, Content and Technology)

11 Sept 2025 · AI in healthcare

Philips urges dedicated health funding in EU long-term budget

5 Sept 2025
Topic — The consultation focuses on the post-2027 EU budget framework to support European competitiveness.
Message — Philips requests that medical technology remains a priority within the new Competitiveness Fund. They argue for maintaining 70% funding rates for large companies in research partnerships. The firm also wants access to innovation funds currently reserved for smaller businesses.123
Why — Maintaining high funding rates and mandatory planning roles would lower the company's investment risks.45
Impact — Startups may face increased competition for innovation funds if the scope expands to large firms.6
Read full response

Response to EU’s next long-term budget (MFF) – EU funding for external action

5 Sept 2025

We welcome that the Global Europe Instrument will fund investment in health infrastructure, building on successful initiatives especially in the European neighbourhood and enlargement candidate countries. Especially the developing situation in Ukraine needs sustainable EU investment, both to respond to the immediate healthcare needs of war and to create a more resilient and sustainable health system for the future.
Read full response

Response to EU’s next long-term budget (MFF) – EU funding for civil protection, preparedness and response to crises

5 Sept 2025

Duly responding to the increasing pressures of disasters and pandemics, the Union Civil Protection Mechanism and Union support for health emergency preparedness and response has as one of its objectives to increase supply of medical devices in the European Union, and fund procurement and stockpiling of medical countermeasures. This funding is crucial to make the actions under the EU Preparedness Union, stockpiling and medical countermeasures strategies a reality.
Read full response

Response to EU’s next long-term budget (MFF) – implementing EU funding with Member States and regions

5 Sept 2025

The new European Fund for economic, social and territorial cohesion, agriculture and rural, fisheries and maritime, prosperity and security rightfully includes in its specific objectives both access to healthcare in rural areas as well as modernization, digitalization and strengthening the quality and resilience of healthcare systems, child and long-term care services. These objectives should be maintained during the legislative process, following successful projects funded under the previous structural as well as regional development and cohesion funds.
Read full response

Philips Urges Climate-Resilient Healthcare Funding and Procurement Reform

4 Sept 2025
Topic — This initiative creates a framework for managing increasing European climate change risks.
Message — Philips advocates for expanded funding of medical stockpiles and digital healthcare innovation. They urge reforming joint procurement to prioritize sustainability and value over price. The company requests long-term public-private partnerships to support market-ready medical technologies.123
Why — This would bolster the medical technology industry's competitiveness through state-supported R&D.4
Impact — Healthcare payers may face higher costs if procurement de-emphasizes low pricing.5
Read full response

Response to Revision of the Standardisation Regulation

18 Jul 2025

Philips welcomes the opportunity to respond to the European Commission's call for evidence on a revision of the Standardisation Regulation 1025/2012. Please see our feedback attached.
Read full response

Meeting with Silke Dalton (Cabinet of Executive Vice-President Henna Virkkunen), Werner Stengg (Cabinet of Executive Vice-President Henna Virkkunen)

17 Jul 2025 · AI

Meeting with Hanna Anttilainen (Cabinet of Executive Vice-President Stéphane Séjourné)

3 Jul 2025 · The SEPs Regulation

Meeting with Lara Wolters (Member of the European Parliament)

26 May 2025 · SEPs + Omnibus

Response to EU Strategy on medical countermeasures

9 May 2025

Many thanks for the opportunity to provide our feedback, please find it in the attached document.
Read full response

Response to Communication on the EU Stockpiling Strategy

9 May 2025

Many thanks for providing our input to the stockpiling strategy, you find it in the attached document.
Read full response

Response to Revision of the EU competition rules on technology transfer agreements (Guidelines)

25 Apr 2025

Koninklijke Philips N.V. (Philips) respectfully submits the attached comments on the Commissions Call for evidence concerning the Technology Transfer Block Exemption Regulation (TTBER).
Read full response

Philips urges EU to simplify medical device regulations and trade

17 Apr 2025
Topic — The European Commission is seeking input on a strategy to boost life science innovation.
Message — Philips calls for a European Life Science Council and the inclusion of large medical device manufacturers. They demand a reduction in regulatory complexity and the removal of transatlantic trade tariffs.123
Why — Streamlining regulations and removing tariffs would significantly reduce Philips’ operational costs and market entry delays.4
Impact — Budget-focused manufacturers would lose their competitive edge as tenders move away from the lowest price.5
Read full response

Meeting with Olivér Várhelyi (Commissioner) and

8 Apr 2025 · Discussion on the future of the European medical devices sector

Meeting with Ekaterina Zaharieva (Commissioner) and

8 Apr 2025 · Exchange on competitiveness and the hurdles to innovation in the EU

Meeting with Stéphane Séjourné (Executive Vice-President) and

8 Apr 2025 · Current economic situation (tariffs), EU regulation, Innovation, Single Market, Public Procurement, Sustainability, data Protection

Meeting with Henna Virkkunen (Executive Vice-President) and

8 Apr 2025 · Discussion on challenges faced by Medtech companies to bring innovation to market

Meeting with Ekaterina Zaharieva (Commissioner) and

8 Apr 2025 · Exchange on competitiveness and the hurdles to innovation in the EU

Meeting with Luis Planas Herrera (Cabinet of Commissioner Jessika Roswall)

17 Mar 2025 · Circular Economy

Philips urges EU to mandate value-based health technology procurement

7 Mar 2025
Topic — The European Commission is evaluating directives governing public procurement of goods and services.
Message — Philips wants to replace the current directive with a regulation for full harmonization. They recommend banning price-only tenders by requiring a 50-60% weighting for value.123
Why — These changes would favor Philips' high-end products over cheaper, lower-quality alternatives.45
Impact — Suppliers of low-cost equipment would lose their competitive advantage based on pricing alone.67
Read full response

Meeting with Bart Groothuis (Member of the European Parliament)

31 Jan 2025 · Health care innovation and investment climate

Philips urges EU to harmonize health technology single market rules

29 Jan 2025
Topic — A consultation on further developing the EU single market for global competitiveness.
Message — Philips requests the preferred adoption of Regulations over Directives to prevent national divergences. They call for a holistic review of product frameworks to simplify and speed up market placement.12
Why — Standardized regulations would reduce compliance costs and accelerate the commercialization of new medical devices.34
Impact — National governments lose the autonomy to set specific local standards for health data and procurement.56
Read full response

Meeting with Laurent Muschel (Acting Director-General Health Emergency Preparedness and Response Authority) and

29 Jan 2025 · Exchange with Royal Philips on upcoming initiatives in the area of health emergencies preparedness and response.

Meeting with Johannes Ten Broeke (Cabinet of Commissioner Wopke Hoekstra)

28 Jan 2025 · Exchange on commercial barriers and opportunities for Philips/healthcare providers in general in the context of EU climate and sustainability policies.

Meeting with Dan Jørgensen (Commissioner) and

23 Jan 2025 · Charting the future of European green competitiveness.

Meeting with Stine Bosse (Member of the European Parliament, Committee chair)

12 Nov 2024 · European health policy

Meeting with Victor Negrescu (Member of the European Parliament, Rapporteur)

8 Nov 2024 · European health and digital policies; EU budget 2025

Meeting with Sebastian Kruis (Member of the European Parliament)

16 Oct 2024 · Developments in health technology sector

Meeting with Peter Van Kemseke (Cabinet of President Ursula von der Leyen)

10 Oct 2024 · EB Summit

Meeting with Ingeborg Ter Laak (Member of the European Parliament)

9 Oct 2024 · Medical devices

Meeting with Miriam Lexmann (Member of the European Parliament)

17 Jul 2024 · EU Competitiveness and priorities for the next mandate

Meeting with Bart Groothuis (Member of the European Parliament)

17 Jul 2024 · Industrial policy

Meeting with Maurits-Jan Prinz (Cabinet of Commissioner Thierry Breton), Valère Moutarlier (Cabinet of Commissioner Thierry Breton)

11 Apr 2024 · Standard Essential Patents

Meeting with Caroline Boeshertz (Cabinet of Executive Vice-President Valdis Dombrovskis), Mirzha De Manuel (Cabinet of Executive Vice-President Valdis Dombrovskis)

19 Mar 2024 · Health industry, competitiveness, sustainability and due diligence

Meeting with Bart Groothuis (Member of the European Parliament)

26 Jan 2024 · SEPs

Meeting with Maurits-Jan Prinz (Cabinet of Commissioner Thierry Breton), Maurits-Jan Prinz (Cabinet of Commissioner Thierry Breton)

23 Jan 2024 · Connected care and Standard Essential Patents

Meeting with Maria da Graça Carvalho (Member of the European Parliament) and FTI Consulting Belgium and

7 Nov 2023 · Cardiovascular Health

Meeting with Catharina Rinzema (Member of the European Parliament)

20 Oct 2023 · SEPs

Meeting with Bart Groothuis (Member of the European Parliament)

20 Oct 2023 · APA meeting on SEPs

Meeting with Tomislav Sokol (Member of the European Parliament, Rapporteur)

3 Oct 2023 · EHDS

Meeting with Sergey Lagodinsky (Member of the European Parliament, Shadow rapporteur)

15 Mar 2023 · AI and Health

Meeting with István Ujhelyi (Member of the European Parliament) and MedTech Europe and Stryker

15 Mar 2023 · European Health Union

Meeting with Lucrezia Busa (Cabinet of Commissioner Didier Reynders)

12 Jan 2023 · Sustainable corporate governance

Meeting with Mairead McGuinness (Commissioner) and

10 Jan 2023 · Taxonomy, ESG ratings, CSRD

Response to Mid-term evaluation of the Recovery and Resilience Facility (2020 – 2024)

6 Dec 2022

Please find attached our observations on the implementation of the Recovery & Resilience Facility in the healthcare area. Philips is available to contribute further to the consultation process and provide our experiences in more detail.
Read full response

Meeting with Jan Huitema (Member of the European Parliament, Shadow rapporteur)

18 Nov 2022 · Ecodesign for Sustainable Products Regulation

Meeting with Tomislav Sokol (Member of the European Parliament, Rapporteur)

25 Oct 2022 · European Health Data Space - EHDS

Meeting with Axel Voss (Member of the European Parliament)

12 Oct 2022 · Artificial Intelligence in Healthcare

Meeting with Antoine Colombani (Cabinet of Executive Vice-President Frans Timmermans) and DSM-Firmenich

12 Sept 2022 · Sustainability reporting

Philips Urges Alignment of Health Data Rules With Existing Laws

19 Jul 2022
Topic — The European Health Data Space proposal regulates the exchange and use of patient data.
Message — Philips requests that the proposal provide clear definitions and alignment with existing laws to avoid regulatory uncertainty. They urge the use of internationally recognized standards for interoperability rather than unique EU specifications. Additionally, the mandate to share data must include safeguards to protect intellectual property and trade secrets.123
Why — Clearer rules would prevent the company from undergoing three separate, costly certification processes for one product.4
Impact — European technology companies could face higher costs and barriers when trying to export products globally.5
Read full response

Philips seeks tighter data rules and 48-month implementation delay

13 May 2022
Topic — This regulation aims to ensure fairness in the allocation of data value.
Message — Philips wants to narrow the definition of data to information actively created by users while excluding trade secrets. They also request extending the implementation period from 12 months to at least 48 months. Additionally, data sharing must not compromise the safety or performance of medical devices.123
Why — Limiting data sharing helps the company protect its intellectual property and innovation.4
Impact — Smaller rivals lose the opportunity to access valuable datasets held by industry leaders.5
Read full response

Meeting with Daniel Mes (Cabinet of Executive Vice-President Frans Timmermans) and Volkswagen Aktiengesellschaft and

7 Apr 2022 · Meeting with CEO Alliance on Digitising Energy Action Plan

Response to Requirements for Artificial Intelligence

6 Aug 2021

Philips welcomes the opportunity to comment on the proposed AI Act. Please see our feedback attached.
Read full response

Meeting with Helena Braun (Cabinet of Executive Vice-President Frans Timmermans)

5 Mar 2021 · Implementation of the EU Circular Economy Action Plan

Response to European Health Emergency Response Authority

24 Feb 2021

On behalf of Philips thank you for the opportunity to comment on the HERA Inception Impact Assessment. Please see our feedback attached. Philips is ready to step up as an effective and reliable partner to establish and support HERA’s mandate.
Read full response

Response to Legislative framework for the governance of common European data spaces

29 Jan 2021

Philips appreciates the opportunity to provide feedback on the European Commission proposal for a Data Governance Act. Please see our detailed feedback attached.
Read full response

Response to A European Health Data Space

29 Jan 2021

Philips appreciates the opportunity to provide feedback on the European Commission initiative to create the European Health Data Space. Please see the detailed feedback attached.
Read full response

Meeting with Frans Timmermans (Executive Vice-President) and Shell Companies and

13 Jan 2021 · Roundtable on the Green Deal, organised by the Dutch Sustainable Growth Coalition, with the participation of the Dutch Prime Minister and other Dutch Government Ministers.

Response to Requirements for Artificial Intelligence

9 Sept 2020

Philips welcomes the opportunity to provide feedback on the roadmap for AI ethical and legal requirements. Please see our feedback in the attachment.
Read full response

Response to Implementing act on a list of High-Value Datasets

21 Aug 2020

Philips welcomes the opportunity to provide feedback on the roadmap for an implementing act on a list of high-value datasets in the context of the Open Data Directive. The development of many products and services depends on data availability. Data generated by the public sector represents an important source of data that can contribute to improving the internal market and to the development of innovative services and products for citizens and businesses. Yet, it is still difficult to find and re-use these data. The Covid-19 crisis has shown the importance and potential of data for crisis management, pandemic monitoring and informed decision-making by governments across Member States in many sectors. For instance, public sector data can serve to better allocate scarce resources for combating infectious diseases and save precious time in emergency response. It is also an important content resource for the development of advanced digital technologies, applications and services, having a transformative effect on many sectors. Further innovation and development of AI-enabled technologies and applications depend on high quality, trustworthy, and accurate health-related data. In healthcare specifically, there is a clear need for the meaningful use of data to improve patient outcomes and access to quality care, reduce costs, support people to live healthy lives and avoid chronic diseases. Statistical data related to health are of significant value for health economic calculations that can help to focus healthcare R&D activities on worthwhile and meaningful initiatives. They are also very useful for predictive analytics in healthcare, i.e. tools that detect and predict the dynamics of an epidemic. We would therefore encourage the Commission to include the following high-value public datasets within the ‘Statistics’ category: - Population health data, including: o Mortality (by demographics, by geography, etc.) o Morbidity (prevalence and incidence, e.g. using diagnostic codes/ICD-10) - Healthcare utilization data, including: o # of GP visits (by geography, aggregated by day or by week) o # of ER visits (by geography, aggregated by day or by week) o Hospital bed occupancy (# and %) o ICU bed occupancy (# and %) o Prevalence and incidence of procedure/treatment categories o Costs to healthcare payers (by DRGs, or by ICD-10, …) - Projections (5-10-15 years) of conditions, morbidities, and costs - Longitudinal data It is important to enable cross-border access to and exchange of public datasets based on common standards across the EU. Selected high-value datasets should not restrict the competitiveness of companies nor lead to the disclosure of confidential data, personal data or IP sensitive elements, including in the context of public procurement or public-private partnerships. In this respect, public authorities should consult relevant stakeholders before releasing such datasets. In conclusion, increased availability of public sector data can bring significant benefits for the society and economy in the EU and contribute to facilitating the rollout of sectoral data spaces in strategic sectors, including the European Health Data Space. Philips offers its support to the European Commission in further refining of the list of high-value datasets. Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in The Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of €19.5 billion and employs approximately 80,000 employees with sales and services in more than 100 countries.
Read full response

Meeting with Mariya Gabriel (Commissioner)

14 May 2020 · Research and Innovation leading to innovative Healthcare solutions, Health private, Public partnerships and Cooperation

Meeting with Margrethe Vestager (Executive Vice-President)

21 Apr 2020 · To discuss response to Covid-19; health data space

Meeting with Frans Timmermans (Executive Vice-President)

21 Apr 2020 · Green recovery and circular economy

Meeting with Thierry Breton (Commissioner) and SANOFI and

6 Apr 2020 · Digitisation of healthcare and innovative e-health solutions.

Meeting with Ursula von der Leyen (President) and

25 Mar 2020 · Videoconference with CEOs on COVID-19

Response to Europe’s Beating Cancer Plan

3 Mar 2020

Philips welcomes the intention of the European Commission to reduce the cancer burden in the EU and to address cancer-related inequalities between and within Member States. We recognize the issues identified in the Roadmap and support the proposed holistic approach towards cancer, including equal access to early diagnosis and treatments, quality of life of patients and their families, and filling the knowledge gaps. Based on our experience of a cancer solutions provider across the EU, we encourage the Commission to consider the following elements in the future EU Beating Cancer Action Plan: • Support deployment of cancer screening programs across the EU. Such support could be two-fold: 1. revising the existing EU screening guidelines for breast, colorectal and cervical cancer, and recommending lung and prostate cancer screening; 2. providing financial incentives within the new Cohesion and Values policies to implement screening programs, especially in Central and Eastern European countries. • Encourage deployment of digital solutions for improving cancer treatment pathways and efficiency of health systems. Today, digital pathology algorithms foster comprehensive diagnosing and AI offers significant potential in cancer detection and treatment. Many of the existing digital solutions trigger new care delivery models that need adequate reimbursement strategies. • Promote holistic, patient-centered approach. While cancer treatments become more and more successful in improving survival rates, still too little attention is given to consequences of cancer therapies on patients, such as heart failure, neurological and immunological disorders, depression, or fatigue. Therefore, designing treatment strategies that have a minimal burden on the patient both during and after the treatment is very important. However, it requires breaking the siloes in care delivery processes, as well as true collaboration between health professionals around the patient. Here, technological solutions exist to enable comprehensive patient-centric care and to support various health professionals in shared decision-making with the patient. • Provide world-class innovation ecosystem for the research on cancer. Two aspects should be taken into account here. On the one hand, regulations should not have one-sided focus on reducing risks, but weigh this against lost value and missed opportunities in innovation. On the other hand, the EU should mobilize investments from the Innovation Funds in the next Multiannual Financial Framework, e.g. Digital Europe, Horizon Europe (including the cancer mission and Public-Private Partnership on Health Innovation) to make the EU the best place for impactful research on cancer. Philips offers its support to the European Commission in further refining of the EU Action Plan. We look forward to contributing to a specific consultation with the technology providers. Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 80,000 employees with sales and services in more than 100 countries.
Read full response

Meeting with Nils Behrndt (Cabinet of Vice-President Neven Mimica)

11 Jun 2019 · Area of possible cooperation on health by private sector

Meeting with Nils Behrndt (Cabinet of Vice-President Neven Mimica)

4 Dec 2018 · Cooperation on health in developing countries through Trust Funds and the External Investment Plan

Meeting with Manuel Mateo Goyet (Cabinet of Commissioner Mariya Gabriel)

4 Dec 2018 · E-Health

Meeting with Annika Nowak (Cabinet of Commissioner Vytenis Andriukaitis)

8 Oct 2018 · Health and research (meeting with 'Scientific Panel for Health')

Meeting with Vytenis Andriukaitis (Commissioner) and

17 Jul 2018 · HTA, digital health and care, medical devices

Meeting with Nils Behrndt (Cabinet of Vice-President Neven Mimica) and Croix Rouge Française and Unknown Organization

16 May 2018 · Funding of health projects under the Trust Fund for the Central African Republic and under the External Investment Plan

Meeting with Marika Lautso-Mousnier (Cabinet of Vice-President Jyrki Katainen)

2 May 2018 · Medical devices & standardisation process

Meeting with Maria-Myrto Kanellopoulou (Cabinet of Vice-President Neven Mimica), Nils Behrndt (Cabinet of Vice-President Neven Mimica)

27 Mar 2018 · Digitisation and development cooperation, in particular in Central African Republic and via the External Investment Plan

Meeting with Jyrki Katainen (Vice-President)

25 Jan 2018 · Circular economy

Meeting with Roberto Viola (Director-General Communications Networks, Content and Technology)

6 Dec 2016 · Digital health

Meeting with Christos Stylianides (Commissioner)

16 Jun 2016 · Discussion on the humanitarian priorities & engagement of the private sector

Meeting with Michael Hager (Digital Economy), Thibaut Kleiner (Digital Economy) and

10 Jun 2016 · Standards/IoT

Meeting with Lowri Evans (Director-General Internal Market, Industry, Entrepreneurship and SMEs)

1 Feb 2016 · Standardisation and intellectual property

Meeting with Nils Behrndt (Cabinet of Vice-President Neven Mimica)

13 Jan 2016 · Private sector involvement in development cooperation with a focus on health care under different frameworks (existing programmes and Trust Funds; SDGs; post Cotonou)

Meeting with Antonio Lowndes Marques De Araujo Vicente (Cabinet of Commissioner Carlos Moedas), Giulia Del Brenna (Cabinet of Commissioner Carlos Moedas)

1 Jul 2015 · Digital Health

Meeting with Miguel Arias Cañete (Commissioner) and

17 Mar 2015 · Energy Union; Päris /COP21; ETS review post 2020

Meeting with Günther Oettinger (Commissioner)

9 Mar 2015 · Active Aging

Meeting with Maroš Šefčovič (Vice-President)

22 Jan 2015 · Bilateral meeting with CEO Eric Rondolat

Meeting with Grzegorz Radziejewski (Cabinet of Vice-President Jyrki Katainen)

7 Jan 2015 · Investment Initiative